Simeprevir plus sofosbuvir in patients with chronic hepatitis C virus genotype 1 infection and cirrhosis: A phase 3 study (OPTIMIST‐2)

2015180 citationsJournal Articlehybrid Open Access

Authors

Eric Lawitz · The University of Texas Health Science Center at San Antonio

Gary Matusow · Hudson Dermatology

Edwin DeJesus · Orlando Immunology Center

Eric M. Yoshida · University of British Columbia

Franco Felizarta · Bakersfield College

Reem Ghalib · Clinical Research Institute

Eliot Godofsky

Abstract

Simeprevir + sofosbuvir for 12 weeks achieved superiority in SVR12 rates versus the historical control in treatment-naive and treatment-experienced HCV GT1-infected patients with cirrhosis and was generally safe and well tolerated. (Hepatology 2016;64:360-369).

Topics & Keywords

Hepatitis C virus research Liver Disease Diagnosis and Treatment Hepatitis B Virus Studies

UN Sustainable Development Goals

Good health and well-being

Publication Details

Published in: Hepatology

Volume 64, Issue 2, pp. 360-369

DOI: 10.1002/hep.28422

Field-Weighted Citation Impact: 23.21